NHRC asks Delhi Govt.for report on administering contaminated injections to GTB Hospital patients

Image
ANI New Delhi [India]
Last Updated : Apr 07 2017 | 7:28 PM IST

The National Human Rights Commission has taken suo motu cognizance of a media report that 20 eye patients had to be rushed to the AIIMS from the Guru Teg Bahadur (GTB) Hospital, Delhi on 2nd April, 2017, when they complained about blurred vision, pain and watery eyes after they were, allegedly, administered contaminated injections at the hospital. About 8 of them reportedly require eye surgery.

The commission has observed that the contents of the news report raise serious issue of negligence by the GTB Hospital doctors and its management, putting the eyesight of the patients to risk. Accordingly, it has issued a notice to the Chief Secretary, Government of NCT of Delhi calling for a detailed report in the matter within four weeks.

According to the media report,20 patients, as part of their follow up treatment, were administered injections containing the drug "Avastian", which is globally used to prevent blindness due to ageing, diabetes, hypertension and rupturing of blood vessels. Reportedly, Dr. Atul Kumar, Chief of the R.P. Centre for Ophthalmic Sciences at AIIMS has said that 'Avastian' is classified as sight saving drug and used all over the world. In this case, it seems that the injections were contaminated, which caused the reaction.

Reportedly, the Medical Director of the GTB Hospital has stated that the samples of the injection have been sent to the microbiology lab for testing so that suspected contamination could be determined. He has informed that specialists were called immediately when the patients complained about blurred vision and mild pain, during the follow up and the serious cases were referred to the AIIMS, New Delhi.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 07 2017 | 6:47 PM IST

Next Story